3.04
+0.14(+4.83%)
Currency In USD
| Previous Close | 2.9 |
| Open | 2.91 |
| Day High | 3.14 |
| Day Low | 2.91 |
| 52-Week High | 5.5 |
| 52-Week Low | 1.11 |
| Volume | 427,721 |
| Average Volume | 1.67M |
| Market Cap | 59.81M |
| PE | -2.13 |
| EPS | -1.43 |
| Moving Average 50 Days | 3.7 |
| Moving Average 200 Days | 2.61 |
| Change | 0.14 |
If you invested $1000 in Annovis Bio, Inc. (ANVS) since IPO date, it would be worth $317 as of January 29, 2026 at a share price of $3.04. Whereas If you bought $1000 worth of Annovis Bio, Inc. (ANVS) shares 5 years ago, it would be worth $304.61 as of January 29, 2026 at a share price of $3.04.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients
GlobeNewswire Inc.
Dec 18, 2025 9:35 PM GMT
Enrollment will begin in January 2026 Participants will be treated with buntanetap for 36 months The study aims to enroll 500 patients MALVERN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a la
Annovis to Host Corporate Update Webinar on January 28, 2026
GlobeNewswire Inc.
Dec 16, 2025 1:00 PM GMT
MALVERN, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease
Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group
GlobeNewswire Inc.
Dec 03, 2025 1:00 PM GMT
MALVERN, Pa., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease